Caplyta® (lumateperone) – New indication
On December 20, 2021, Intra-Cellular Therapies announced the FDA approval of Caplyta (lumateperone), for the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate.
Top